Routine blood tests to predict liver fibrosis in chronic hepatitis C

Table 4 Correlation between fibrosis score and aspartate aminotransferase-to-platelet ratio index, aspartate aminotransferase/alanine aminotransferase ratio, and FibroQ, FIB-4, cirrhosis discriminant score, age-platelet index, Lok’s model, Pohl score

Metavir fibrosis score	F1	F2	F3	F4
Patient number (%)	41 (17.3)	85 (35.9)	98 (41.4)	13 (5.5)
AAR	0.566 ± 0.162ce	0.673 ± 0.250	0.749 ± 0.222	0.776 ± 0.175
APRI	1.433 ± 1.040a	1.919 ± 1.904	2.320 ± 1.390	2.508 ± 1.102
FibroQ	1.485 ± 0.855gi	2.532 ± 1.660m	3.563 ± 2.056	3.581 ± 1.812
FIB-4	1.79 ± 1.13gim	2.79 ± 2.03	3.75 ± 1.97	3.82 ± 1.57
CDS	5.61 ± 1.16	5.69 ± 1.19	6.14 ± 1.12	6.15 ± 1.41
API	3.95 ± 2.06gim	5.25 ± 2.24	6.40 ± 2.29	6.15 ± 1.63
Lok’s model	0.22 ± 0.12kmo	0.32 ± 0.18	0.43 ± 0.19	0.46 ± 0.18
Pohl score	0	0.01 ± 0.11	0.08 ± 0.28	0.04 ± 0.19

^aP < 0.05, F1 vs F3;

^cP < 0.01, F1 vs F3;

^eP < 0.05, F1 vs F4;

^gP < 0.05, F1 vs F2;

ⁱP < 0.01, F1 vs F3 and F4;

^kP < 0.01, F1 vs F2, F3 and F4;

^mP < 0.01, F2 vs F3;

^oP < 0.05, F2 vs F4. AAR: AST/ALT ratio; APRI: AST-to-platelet ratio index; AST: Aspartate aminotransferase; ALT: Alanine aminotransferase; API: Age-platelet index; CDS: Cirrhosis discriminant score.